KORU Medical Systems Announces Novel Therapies Collaboration For Late-Stage Endocrinological Biologic
Portfolio Pulse from Happy Mohamed
KORU Medical Systems, Inc. (NASDAQ:KRMD) has announced a collaboration with a biopharmaceutical company to validate its FREEDOM™ Infusion System for use with the biopharma company's novel biologic. The drug developer is expected to begin Phase III studies by the end of 2023 for treatment of a rare genetic disease. This agreement adds to KORU Medical's previously announced collaborations for Phase II and Phase III studies of treatments for various diseases.
July 27, 2023 | 8:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
KORU Medical's new collaboration could potentially expand its product usage and market reach, potentially leading to increased revenues in the future.
The collaboration with the biopharmaceutical company for the validation of KORU's FREEDOM™ Infusion System for use with a novel biologic could potentially expand the usage of KORU's product. This, coupled with the fact that the drug is for a rare genetic disease that currently has no pharmaceutical treatments, could lead to a significant increase in KORU's market reach and future revenues.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100